Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on December 27, 2013, reporting events occurring on that date. The Company is a biopharmaceutical firm focused on cell therapy programs for cardiovascular applications, with its lead product being CAP-1002.
Key Financial Metrics and Material Changes
The filing details a significant material definitive agreement rather than periodic financial results. Key financial terms include:
- Upfront Payment: Capricor received an immediate cash payment of $12.5 million from Janssen Biotech, Inc.
- Potential Future Revenue: If Janssen exercises its option, Capricor could receive an upfront license fee and milestone payments totaling up to $325.0 million.
- Royalties: The agreement includes a double-digit royalty on commercial sales of licensed products.
- Cost Sharing: Capricor will contribute to the costs of developing a chemistry, manufacturing, and controls (CMC) package.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period, as this is a current report on specific events rather than a financial statement.
Guidance, Outlook, and Management Commentary
Management highlighted the strategic collaboration with Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) to develop CAP-1002 and cell manufacturing capabilities. The agreement grants Janssen an exclusive option to license CAP-1002 and certain allogeneic cardiospheres for cardiology applications worldwide. This option is exercisable until 60 days after Capricor delivers six-month follow-up results from the Phase II ALLSTAR clinical trial. The Company intends to seek confidential treatment for certain terms of the agreement.
Other Events
The Company confirmed that its common stock is trading on the OTC Markets under the new ticker symbol "CAPR," effective December 20, 2013. There are approximately 11,687,430 shares of common stock issued and outstanding.
Investor Verification Checklist
- Verify the receipt of the $12.5 million upfront payment in the Company's cash position.
- Monitor the progress and results of the Phase II ALLSTAR clinical trial for CAP-1002, as this triggers the option exercise window.
- Review the full text of the Collaboration Agreement and License Option when filed as an exhibit to the Form 10-K for the year ended December 31, 2013.
- Confirm the specific terms of the "double-digit royalty" and the structure of the $325.0 million in potential milestone payments.